Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Up 45.6% in October

Clearmind Medicine Inc. (NASDAQ:CMNDGet Free Report) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 316,600 shares, a growth of 45.6% from the October 15th total of 217,400 shares. Based on an average daily trading volume, of 377,300 shares, the short-interest ratio is currently 0.8 days. Currently, 10.5% of the shares of the company are short sold.

Clearmind Medicine Trading Down 8.8 %

NASDAQ:CMND traded down $0.13 during mid-day trading on Friday, hitting $1.34. The company’s stock had a trading volume of 284,485 shares, compared to its average volume of 1,358,733. Clearmind Medicine has a fifty-two week low of $0.92 and a fifty-two week high of $6.80. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.71 and a current ratio of 1.71. The stock has a fifty day moving average of $1.37 and a 200-day moving average of $1.36.

Clearmind Medicine (NASDAQ:CMNDGet Free Report) last posted its quarterly earnings results on Monday, September 16th. The company reported ($0.59) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Clearmind Medicine stock. Cornerstone Wealth Group LLC acquired a new position in shares of Clearmind Medicine Inc. (NASDAQ:CMNDFree Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,000 shares of the company’s stock, valued at approximately $34,000. Cornerstone Wealth Group LLC owned about 1.18% of Clearmind Medicine at the end of the most recent quarter. Hedge funds and other institutional investors own 96.05% of the company’s stock.

Clearmind Medicine Company Profile

(Get Free Report)

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.

Featured Stories

Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.